Characteristics of 31 immunocompromised patients with protracted COVID-19 who received vax-plasma transfusion stratified by patient
| No. . | Diagnosis . | Before vax-plasma . | Vax-plasma . | Outcomes . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Prev. hosp. . | Previous therapies . | WHO∗ . | ICU . | Time to Tx, d . | Transfusions, No. . | Discharge, d . | Survival . | |||||
| R . | S . | mAb . | CCP19 . | |||||||||
| 1 | CLL | 1 | ● | ● | 6 | Yes | 2 | 2 | 3 | Yes | ||
| 2 | CLL | 1 | ● | ● | ● | 4 | – | 386 | 1 | 1 | Yes | |
| 3 | CLL | 0 | ● | ● | 4 | – | 31 | 2 | 5 | Yes | ||
| 4 | CLL | 0 | ● | 4 | – | 41 | 2 | 1 | Yes | |||
| 5 | CLL | 0 | ● | ● | ● | 7 | Yes | 29 | 2 | – | No | |
| 6 | MCL | 11 | ● | ● | ● | 3 | – | 281 | 6 | – | Yes | |
| 7 | MCL | 1 | ● | ● | ● | 4 | – | 389 | 2 | 3 | Yes | |
| 8 | MCL | 0 | ● | 4 | – | 1 | 2 | 1 | Yes | |||
| 9 | MCL | 0 | ● | ● | 5 | Yes | 14 | 1 | 3 | Yes | ||
| 10 | MCL | 0 | ● | ● | 5 | – | 1 | 1 | 3 | Yes | ||
| 11 | MM | 1 | ● | ● | ● | 5 | Yes | 13 | 3 | 16 | Yes | |
| 12 | MM | 0 | ● | ● | 4 | – | 3 | 1 | 4 | Yes | ||
| 13 | MM | 0 | ● | ● | ● | 4 | – | 25 | 1 | 20 | Yes | |
| 14 | MM | 0 | ● | ● | 4 | – | 55 | 1 | 4 | Yes | ||
| 15 | AML | 2 | ● | ● | 5 | – | 32 | 2 | 13 | Yes | ||
| 16 | AML | 0 | ● | ● | 7 | Yes | 2 | 1 | – | No | ||
| 17 | DLBCL | 2 | ● | ● | ● | 5 | – | 41 | 2 | 4 | Yes | |
| 18 | DLBCL | 1 | ● | 6 | Yes | 32 | 2 | – | No | |||
| 19 | ALL | 0 | ● | 4 | – | 1 | 1 | 19 | Yes | |||
| 20 | FL | 1 | ● | ● | ● | 4 | – | 161 | 2 | 1 | Yes | |
| 21 | RA | 2 | ● | ● | 3 | – | 340 | 2 | – | Yes | ||
| 22 | RA | 1 | ● | ● | ● | 5 | – | 31 | 3 | 4 | Yes | |
| 23 | RA | 0 | ● | ● | 4 | – | 3 | 2 | 1 | Yes | ||
| 24 | RA | 1 | ● | ● | 5 | Yes | 65 | 1 | – | No | ||
| 25 | Lupus | 1 | ● | ● | 4 | Yes | 35 | 1 | 109 | Yes | ||
| 26 | SOT | 2 | ● | ● | 6 | Yes | 6 | 1 | 23 | Yes | ||
| 27 | SOT | 0 | ● | ● | 5 | Yes | 3 | 2 | 7 | Yes | ||
| 28 | SOT, Lupus | 0 | ● | ● | 7 | Yes | 19 | 2 | – | No | ||
| 29 | MS | 0 | ● | ● | 4 | – | 23 | 1 | 4 | Yes | ||
| 30 | CVID, MALT | 2 | ● | ● | ● | 5 | Yes | 384 | 11 | 5 | Yes | |
| 31 | DL-GNT | 0 | ● | 4 | – | 2 | 1 | 3 | Yes | |||
| No. . | Diagnosis . | Before vax-plasma . | Vax-plasma . | Outcomes . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Prev. hosp. . | Previous therapies . | WHO∗ . | ICU . | Time to Tx, d . | Transfusions, No. . | Discharge, d . | Survival . | |||||
| R . | S . | mAb . | CCP19 . | |||||||||
| 1 | CLL | 1 | ● | ● | 6 | Yes | 2 | 2 | 3 | Yes | ||
| 2 | CLL | 1 | ● | ● | ● | 4 | – | 386 | 1 | 1 | Yes | |
| 3 | CLL | 0 | ● | ● | 4 | – | 31 | 2 | 5 | Yes | ||
| 4 | CLL | 0 | ● | 4 | – | 41 | 2 | 1 | Yes | |||
| 5 | CLL | 0 | ● | ● | ● | 7 | Yes | 29 | 2 | – | No | |
| 6 | MCL | 11 | ● | ● | ● | 3 | – | 281 | 6 | – | Yes | |
| 7 | MCL | 1 | ● | ● | ● | 4 | – | 389 | 2 | 3 | Yes | |
| 8 | MCL | 0 | ● | 4 | – | 1 | 2 | 1 | Yes | |||
| 9 | MCL | 0 | ● | ● | 5 | Yes | 14 | 1 | 3 | Yes | ||
| 10 | MCL | 0 | ● | ● | 5 | – | 1 | 1 | 3 | Yes | ||
| 11 | MM | 1 | ● | ● | ● | 5 | Yes | 13 | 3 | 16 | Yes | |
| 12 | MM | 0 | ● | ● | 4 | – | 3 | 1 | 4 | Yes | ||
| 13 | MM | 0 | ● | ● | ● | 4 | – | 25 | 1 | 20 | Yes | |
| 14 | MM | 0 | ● | ● | 4 | – | 55 | 1 | 4 | Yes | ||
| 15 | AML | 2 | ● | ● | 5 | – | 32 | 2 | 13 | Yes | ||
| 16 | AML | 0 | ● | ● | 7 | Yes | 2 | 1 | – | No | ||
| 17 | DLBCL | 2 | ● | ● | ● | 5 | – | 41 | 2 | 4 | Yes | |
| 18 | DLBCL | 1 | ● | 6 | Yes | 32 | 2 | – | No | |||
| 19 | ALL | 0 | ● | 4 | – | 1 | 1 | 19 | Yes | |||
| 20 | FL | 1 | ● | ● | ● | 4 | – | 161 | 2 | 1 | Yes | |
| 21 | RA | 2 | ● | ● | 3 | – | 340 | 2 | – | Yes | ||
| 22 | RA | 1 | ● | ● | ● | 5 | – | 31 | 3 | 4 | Yes | |
| 23 | RA | 0 | ● | ● | 4 | – | 3 | 2 | 1 | Yes | ||
| 24 | RA | 1 | ● | ● | 5 | Yes | 65 | 1 | – | No | ||
| 25 | Lupus | 1 | ● | ● | 4 | Yes | 35 | 1 | 109 | Yes | ||
| 26 | SOT | 2 | ● | ● | 6 | Yes | 6 | 1 | 23 | Yes | ||
| 27 | SOT | 0 | ● | ● | 5 | Yes | 3 | 2 | 7 | Yes | ||
| 28 | SOT, Lupus | 0 | ● | ● | 7 | Yes | 19 | 2 | – | No | ||
| 29 | MS | 0 | ● | ● | 4 | – | 23 | 1 | 4 | Yes | ||
| 30 | CVID, MALT | 2 | ● | ● | ● | 5 | Yes | 384 | 11 | 5 | Yes | |
| 31 | DL-GNT | 0 | ● | 4 | – | 2 | 1 | 3 | Yes | |||
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CCP19; coronavirus disease 2019 convalescent plasma; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; DL-GNT, diffuse leptomeningeal disseminated glioneuronal tumor; FL, follicular lymphoma; mAb, neutralizing antispike monoclonal antibody; ICU, intensive care unit admission; MALT, mucosa-associated lymphoid tissue; MCL, mantle cell lymphoma; MM, multiple myeloma; No., number; Prev. hosp., number of previous hospitalizations for COVID-19; R, remdesivir; RA, rheumatoid arthritis; S, steroid; Tx, treatment; WHO, World Health Organization.
● Indicate previous or concomitant therapies for COVID-19 specific treatments received by each patient.
WHO Disease Severity Scale: 3, not hospitalized; 4, hospitalized, no supplemental oxygen; 5, hospitalized, nonhigh flow supplemental oxygen; 6, hospitalized, high flow supplemental oxygen; 7, hospitalized, intubated or extracorporeal membrane oxygenation; 8, deceased.